SEARCH
NEWARK,U.S.A.andNANJING,China.July31,2023–BiosionUSA,Inc.(Biosion),aglobalclinical-stageR&Dbiotechnologycompany,todayannouncedthephase2studyinitiationfortheevaluationofBSI-045B,ananti-TLSPmAb,in...2023-07-31
Newark,DE,U.S.andNanjing,China–July5,2023.Biosion,Inc.(Biosion),aglobal,clinical-stagebiotechnologycompany,todayannouncedtheappointmentofFurqanAhmed,PharmD.,astheVicePresidentandHeadofBusinessDe...2023-07-05
NEWARK,U.S.A.andNANJING,China.May31,2023–ThepartnerofBiosion,Inc.(Biosion),CelldexTherapeutics,Inc.(NASDAQ:CLDX)todayannouncedthatthefirstpatienthasbeendosedinaPhase1studyofCDX-585.CDX-585combin...2023-06-09
- 192023-09Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in Atopic Dermatitis (ADAMANT)
- 192023-09Biosion, Inc. Appoints Furqan Ahmed, PharmD as Vice President and Head of Business Development
- 192023-09Biosion’s Partner Celldex Therapeutics Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies
- 192023-09Biosion’s Partner Pyxis Oncology Announces First Patient Dosed in Phase 1 Study of PYX-106
- 192023-09Biosion Presents Discovery and Development Data at PEGS for its Anti-CD40 Agonistic Antibody
- 192023-09Biosion bispecific antibody therapies to be featured at the American Association for Cancer Research (AACR) annual meeting 2023
- 1
- 2
- 3
- 4
COPYRIGHT © 2023.
BIOSION ALL RIGHTS RESERVED.
BIOSION ALL RIGHTS RESERVED.
Biosion USA, Inc. 1 Innovation Way, Suite 300, Newark, Delaware 19711, USA
Copyright © 2022. Biosion All rights reserved. 苏ICP备2022027163号
Biosion USA, Inc. 1 Innovation Way, Suite 300, Newark, Delaware 19711, USA
BD@Biosion.com
1-302-257-5085
SEARCH
- Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in Atopic Dermatitis (ADAMANT)2023-07-31
- Biosion, Inc. Appoints Furqan Ahmed, PharmD as Vice President and Head of Business Development2023-07-05
- Biosion’s Partner Celldex Therapeutics Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies2023-06-09
- 312023-07Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in Atopic Dermatitis (ADAMANT)
- 052023-07Biosion, Inc. Appoints Furqan Ahmed, PharmD as Vice President and Head of Business Development
- 092023-06Biosion’s Partner Celldex Therapeutics Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies
- 312023-05Biosion’s Partner Pyxis Oncology Announces First Patient Dosed in Phase 1 Study of PYX-106
- 072023-05Biosion Presents Discovery and Development Data at PEGS for its Anti-CD40 Agonistic Antibody
- 202023-03Biosion bispecific antibody therapies to be featured at the American Association for Cancer Research (AACR) annual meeting 2023
- 1
- 2
- 3
- 4
COPYRIGHT © 2023.
BIOSION ALL RIGHTS RESERVED.
BIOSION ALL RIGHTS RESERVED.
Biosion USA, Inc. 1 Innovation Way, Suite 300, Newark, Delaware 19711, USA
Copyright © 2022. Biosion All rights reserved. 苏ICP备2022027163号
Biosion USA, Inc. 1 Innovation Way, Suite 300, Newark, Delaware 19711, USA
BD@Biosion.com
1-302-257-5085